• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.METTL4和METTL5作为肝细胞癌患者无复发生存的生物标志物。
Future Oncol. 2025 Feb;21(3):331-340. doi: 10.1080/14796694.2024.2442296. Epub 2024 Dec 20.
2
Cluster analysis of hepatocellular carcinoma prognosis using preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin levels: a multi-institutional study.利用术前甲胎蛋白和异常凝血酶原水平对肝细胞癌预后进行聚类分析：一项多机构研究
J Gastrointest Surg. 2025 Apr;29(4):101980. doi: 10.1016/j.gassur.2025.101980. Epub 2025 Jan 28.
3
Bioinformatics identification of key microRNA-correlated genes associated with hepatocellular carcinoma heterogeneity and prognosis.与肝细胞癌异质性和预后相关的关键微小RNA相关基因的生物信息学鉴定
BMC Gastroenterol. 2025 Jul 1;25(1):452. doi: 10.1186/s12876-025-04031-6.
4
Enhancing Recurrence-Free Survival Prediction in Hepatocellular Carcinoma: A Time-Updated Model Incorporating Tumor Burden and AFP Dynamics.提高肝细胞癌无复发生存预测：一种纳入肿瘤负荷和甲胎蛋白动态变化的时间更新模型
Ann Surg Oncol. 2025 Apr 16. doi: 10.1245/s10434-025-17303-y.
5
LZTR1 expression as a novel predictive biomarker for early recurrence of hepatocellular carcinoma.LZTR1表达作为肝细胞癌早期复发的一种新型预测生物标志物。
Eur J Med Res. 2025 Jun 20;30(1):500. doi: 10.1186/s40001-025-02791-1.
6
TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis.端粒酶逆转录酶-TP53突变：一种用于肝细胞癌复发和预后的新型生物标志物组合
Sci Rep. 2025 Jan 29;15(1):3620. doi: 10.1038/s41598-025-87545-z.
7
Evaluation and verification of MPDZ as a prognostic biomarker for hepatocellular carcinoma through multiple databases.通过多个数据库评估和验证MPDZ作为肝细胞癌的预后生物标志物
Clin Exp Med. 2025 Jun 18;25(1):209. doi: 10.1007/s10238-025-01729-5.
8
Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.祖细胞标志物可预测米兰标准以外行肝移植的肝细胞癌患者的预后。
J Hepatol. 2015 Dec;63(6):1368-77. doi: 10.1016/j.jhep.2015.07.025. Epub 2015 Jul 26.
9
Predictive effect and clinical diagnosis significance of exosome-related genes for nonalcoholic fatty liver disease-related hepatocellular carcinoma.外泌体相关基因对非酒精性脂肪性肝病相关肝细胞癌的预测作用及临床诊断意义
Sci Rep. 2025 Jul 2;15(1):23062. doi: 10.1038/s41598-025-07286-x.
10
Multi-omics analysis identifies SNP-associated immune-related signatures by integrating Mendelian randomization and machine learning in hepatocellular carcinoma.多组学分析通过整合孟德尔随机化和机器学习在肝细胞癌中识别与单核苷酸多态性相关的免疫相关特征。
Sci Rep. 2025 Jul 4;15(1):23930. doi: 10.1038/s41598-025-09010-1.

引用本文的文献

1
Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies.解码肿瘤微环境中的代谢对话：从免疫抑制到精准癌症治疗
Exp Hematol Oncol. 2025 Jul 22;14(1):99. doi: 10.1186/s40164-025-00689-6.

本文引用的文献

1
New insights on the interaction between mA modification and non-coding RNA in cervical squamous cell carcinoma.关于在宫颈鳞癌中 mA 修饰与非编码 RNA 相互作用的新见解。
World J Surg Oncol. 2023 Jan 30;21(1):25. doi: 10.1186/s12957-023-02907-z.
2
METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.METTL5 通过促进 USP5 翻译来稳定 c-Myc，从而重新编程葡萄糖代谢并促进肝细胞癌的进展。
Cancer Commun (Lond). 2023 Mar;43(3):338-364. doi: 10.1002/cac2.12403. Epub 2023 Jan 5.
3
METTL4-mediated nuclear N6-deoxyadenosine methylation promotes metastasis through activating multiple metastasis-inducing targets.METTL4 介导的核 N6-去氧腺苷甲基化通过激活多个促进转移的靶标促进转移。
Genome Biol. 2022 Dec 2;23(1):249. doi: 10.1186/s13059-022-02819-3.
4
STMN1 as a novel prognostic biomarker in HCC correlating with immune infiltrates and methylation.STMN1 作为 HCC 的一种新型预后生物标志物，与免疫浸润和甲基化相关。
World J Surg Oncol. 2022 Sep 20;20(1):301. doi: 10.1186/s12957-022-02768-y.
5
Diagnostic Value of Multislice Spiral Computed Tomography Combined with Serum AFP, TSGF, and GP73 Assay in the Diagnosis of Primary Liver Cancer.多层螺旋计算机断层扫描联合血清甲胎蛋白、肿瘤特异性生长因子及高尔基体蛋白73检测在原发性肝癌诊断中的价值
Evid Based Complement Alternat Med. 2022 Jun 7;2022:6581127. doi: 10.1155/2022/6581127. eCollection 2022.
6
Loss of mA Methyltransferase METTL5 Promotes Cardiac Hypertrophy Through Epitranscriptomic Control of SUZ12 Expression.mA甲基转移酶METTL5的缺失通过对SUZ12表达的表观转录组调控促进心肌肥大。
Front Cardiovasc Med. 2022 Feb 28;9:852775. doi: 10.3389/fcvm.2022.852775. eCollection 2022.
7
The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma.甲基转移酶样蛋白 5 在子宫体子宫内膜癌错配修复缺陷中的潜在作用。
Bioengineered. 2022 Mar;13(3):5525-5536. doi: 10.1080/21655979.2022.2036912.
8
as biomarker in hepatitis B virus-associated hepatocellular carcinoma.作为乙型肝炎病毒相关肝细胞癌中的生物标志物。
J Cancer. 2021 Apr 19;12(12):3486-3500. doi: 10.7150/jca.46579. eCollection 2021.
9
Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas.METTL5相关的预后特征构建及其在肺腺癌中的免疫意义综合分析
Front Genet. 2021 Feb 19;11:617174. doi: 10.3389/fgene.2020.617174. eCollection 2020.
10
Ribosome 18S mA Methyltransferase METTL5 Promotes Translation Initiation and Breast Cancer Cell Growth.核糖体18S mA甲基转移酶METTL5促进翻译起始和乳腺癌细胞生长。
Cell Rep. 2020 Dec 22;33(12):108544. doi: 10.1016/j.celrep.2020.108544.

METTL4和METTL5作为肝细胞癌患者无复发生存的生物标志物。

METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.

作者信息

Zhao Jialing, Sun Ruiqi, Zhi Liang, Guo Danjing, Ling Sunbin, Liang Xiangnan, Li Jianhui, Jia Changku

机构信息

Zhejiang University School of Medicine, Hangzhou, China.

Department of Hepatobiliary and Pancreatic Surgery, Hangzhou First People's Hospital, Hangzhou, China.

出版信息

Future Oncol. 2025 Feb;21(3):331-340. doi: 10.1080/14796694.2024.2442296. Epub 2024 Dec 20.

DOI:10.1080/14796694.2024.2442296
PMID:39706798
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11792863/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with high rates of postoperative recurrence. Identifying reliable biomarkers for predicting recurrence is critical for improving patient outcomes. This study investigates the predictive value of m6A methylation-related genes, METTL4 and METTL5, on HCC recurrence after surgery.

RESEARCH DESIGN AND METHODS

We analyzed METTL4 and METTL5 expression in HCC and adjacent non-cancerous tissues using the TCGA database and evaluated their levels in surgical samples from 67 hCC patients. A recurrence risk model was developed and validated in an external cohort of 65 patients.

RESULTS

METTL4 and METTL5 were significantly overexpressed in HCC tissues. High expression correlated with shorter recurrence-free survival (RFS). The model stratified patients into high, medium, and low-risk groups with 3-year RFS rates of 18.75%, 69.70%, and 93.75%, respectively.

CONCLUSIONS

METTL4 and METTL5 expression levels are strong predictors of HCC recurrence. The risk model offers a novel approach for postoperative management of HCC.

摘要

背景

肝细胞癌（HCC）是癌症相关死亡的主要原因，术后复发率高。识别可靠的预测复发的生物标志物对于改善患者预后至关重要。本研究调查了m6A甲基化相关基因METTL4和METTL5对HCC术后复发的预测价值。

研究设计与方法

我们使用TCGA数据库分析了HCC组织和癌旁非癌组织中METTL4和METTL5的表达，并评估了67例HCC患者手术样本中的表达水平。在一个65例患者的外部队列中建立并验证了复发风险模型。

结果

METTL4和METTL5在HCC组织中显著过表达。高表达与无复发生存期（RFS）缩短相关。该模型将患者分为高、中、低风险组，3年RFS率分别为18.75%、69.70%和93.75%。

结论

METTL4和METTL